menu
    • menu
    [{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Series A Financing","leadProduct":"Protein-based Therapeutic","moa":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nuvig Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Inhalation","sponsorNew":"Nuvig Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Nuvig Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"NVG-2089","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Nuvig Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Nuvig Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvig Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Nuvig Therapeutics

    Menu

    Nuvig Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nuvig Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Nuvig Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVG-2089

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089

                            Details : NVG-2089 is a recombinant immunomodulator targeting type II Fc receptors, developed for inflammatory myopathies and severe autoimmune skin diseases.

                            Brand Name : NVG-2089

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 12, 2024

                            Lead Product(s) : NVG-2089

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nuvig Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Nuvig Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Protein-based Therapeutic

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Novo Holdings

                            Deal Size : $47.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases

                            Details : Nuvig is building a pipeline of differentiated protein therapeutics that specifically target affected tissues in a disease-specific manner and can be used in the context of varied but well-defined disease mechanisms.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 11, 2022

                            Lead Product(s) : Protein-based Therapeutic

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Novo Holdings

                            Deal Size : $47.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth